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Abstract
The Vaccine Safety Datalink (VSD) is a collaborative project between the Centers for Disease 
Control and Prevention(CDC) and 9 health care organizations. Established in 1990, VSD is a vital 
resource informing policy makers and the public about the safety of vaccines used in the United 
States. Large linked databases are used to identify and evaluate adverse events in over 9 million 
individuals annually. VSD generates rapid, important safety assessments for both routine 
vaccinations and emergency vaccination campaigns. VSD monitors safety of seasonal influenza 
vaccines in near-real time, and provided essential information on the safety of influenza A (H1N1) 
2009 monovalent vaccine during the recent pandemic. VSD investigators have published important 
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studies demonstrating that childhood vaccines are not associated with autism or other 
developmental disabilities. VSD prioritizes evaluation of new vaccines; searches for possible 
unusual health events after vaccination; monitors vaccine safety in pregnant women; and has 
pioneered development of biostatistical research methods.
Keywords
Surveillance; Vaccine safety; Immunization
1. Introduction
Vaccines are considered one of the most important public health successes of the last 
century. They have led to significant reductions in morbidity and mortality from many 
infectious diseases [1]. The success of vaccination programs depends not only on vaccines’ 
effectiveness, but also their safety. As vaccine-preventable diseases become increasingly 
unusual, the public becomes less familiar with these diseases and consequently focuses more 
intently on vaccine safety [2]. Widespread concerns about the occurrence of adverse events 
can lead to a loss of confidence in the safety of vaccines, lower vaccination rates and 
resurgence in vaccine-preventable diseases [2,3].
The safety of vaccines is assessed through rigorous clinical trials before they are licensed. 
However, clinical trials’ primary focus is on efficacy; they generally lack adequate sample 
size and they may also have insufficient follow-up time to identify rare adverse events or 
those with delayed onset [4]. Further, inclusion in prelicensure trials is typically limited to 
healthy individuals, and trials often specifically exclude specific vulnerable sub-populations, 
such as pregnant women, for whom a vaccine may be indicated. Thus, monitoring vaccines 
once they are used in the general population is required to detect rare adverse reactions, 
those that may occur long after vaccination, and those that may affect specific sub-
populations.
2. History of vaccine safety monitoring and the Vaccine Safety Datalink
In the U.S., programs to monitor vaccine safety began in the late 1970s. Established by CDC 
in 1978 and continuing until 1990, the Monitoring System for Adverse Events Following 
Immunizations (MSAEFI) collected reports from the parents or guardians of children who 
received publicly funded vaccines concerning adverse events following immunization [5]. 
The National Childhood Vaccine Injury Act (NCVIA) of 1986 was landmark legislation that 
established The National Vaccine Program Office, the Vaccine Injury Compensation 
Program, and the Vaccine Adverse Event Reporting System (VAERS); VAERS replaced 
MSAEFI in 1990 [6]. VAERS is co-managed by CDC and the Food and Drug 
Administration (FDA). VAERS reports are accepted from any reporter; including vaccine 
manufacturers, immunization programs, health care providers, patients, parents, and others 
[6]. This nationwide system allows for timely detection of possible vaccine safety problems. 
However, VAERS reporting is voluntary. Thus, VAERS has important limitations [6], 
including underreporting and incomplete reports. VAERS usually cannot be used to 
determine whether an adverse event is caused by a vaccine or is simply coincidental. Rates 
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or relative risks of vaccine adverse events also cannot be determined because the number of 
people vaccinated in the population (i.e. the denominator) and reporting rates are unknown, 
and there are no unvaccinated comparison groups in VAERS data.
Recognizing the need for a flexible, timely and robust system to evaluate vaccine safety and 
supplement information provided by VAERS, CDC established the Vaccine Safety Datalink 
(VSD) in 1990 to conduct post-marketing vaccine safety evaluations in defined populations 
[3,7]. As a collaboration between CDC and several large health care organizations, VSD 
conducts population-based monitoring and research on important immunization safety 
questions. VSD provides scientific data to healthcare providers, public health officials, and 
others to inform national immunization policy, and helps to ensure that the public has the 
best available timely information regarding the safety of immunization.
Beginning as a collaboration between CDC and four health care organizations (i.e., sites), 
encompassing 6 million persons, to study the safety of childhood immunizations, VSD has 
expanded to include 9 sites that can evaluate vaccine safety for all age groups (Fig. 1). 
Working with CDC investigators as a multidisciplinary team, site scientific investigators 
provide clinical, methodological, and data expertise. The leadership and vision of this 
collaboration has played an essential role in the US vaccine safety monitoring enterprise and 
fostered innovation in the development of databases and methods to monitor and evaluate 
vaccine safety. VSD has systematically built the capacity to address a wide array of safety 
issues, including monitoring new vaccines in children and adults, and has become 
recognized as a model system for conducting timely vaccine safety evaluations. The 
aggregate population across all sites is sufficiently large so that risk can be assessed for rare 
adverse events. VSD has cumulative information on more than 21 million individuals who 
have collectively received over 134 million vaccine doses. Data from approximately 9.3 
million individuals are available annually, including 2.1 million children and 7.2 million 
adults (Table 1).
Although VSD comprises a population of over 9 million people annually, the size of the 
population may not be adequate to evaluate extremely rare outcomes (e.g., Stevens Johnson 
Syndrome). This may be most concerning during situations of a mass vaccination campaign 
in which a large number of vaccinations are administered in a short period of time and there 
is priority in identifying potential safety problems as soon as possible. Seasonal influenza 
vaccination is administered in nearly a mass campaign paradigm. In VSD, approximately 3.8 
million doses of influenza vaccine are administered each year, with 80–90% administered 
during September through November. In this situation, we have estimated that for a rare 
condition such as Guillain-Barré Syndrome (GBS) that has a background incidence of 1 per 
100,000 people per year, VSD could detect an increased risk of 1 per million within 10 
weeks of the start of vaccination.
VSD conducts studies to test hypotheses regarding vaccine-related adverse events and to 
identify safety signals using near real-time monitoring. To achieve these goals, VSD requires 
that participating sites: (1) maintain computerized data bases of healthcare encounters, 
including computerized immunization registries with detailed information on vaccines 
administered; (2) have the capability to access written or electronic medical records and 
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other data sources to provide detailed information on specific healthcare encounters; and (3) 
provide integrated healthcare services to their members so that the full spectrum of 
healthcare from outpatient clinic and emergency department (ED) visits to hospitalizations 
can be captured. In addition, each site has scientists with expertise in vaccine safety, 
statistical analysis, and data management.
3. A history of innovation
With over 20 years of data collected in a standardized format, VSD has the unique ability to 
conduct timely vaccine safety studies, including assessments of rare adverse events and 
longitudinal studies involving prolonged follow-up of individual patients. VSD has 
innovated and continues to innovate in linking data files to address questions, while 
protecting patient confidentiality. A recent priority of VSD has been the establishment of a 
“pregnancy platform” to effectively monitor and conduct targeted research on the safety of 
vaccinations given during pregnancy (e.g., influenza, Tdap) identifying potential adverse 
outcomes in both pregnant women and their offspring. The ability to conduct long term 
follow up of birth cohorts over multiple years in VSD was also effectively demonstrated in 
VSD’s evaluation of thimerosal exposure in early life and neuropsychological outcomes 7–
10 years later [8].
A strength of VSD is the collaboration of the site investigators in the analyses: when data are 
combined, investigators/staff at each site contribute their expertise in understanding and 
interpreting their own data, which enables each study to incorporate the differences among 
sites in diagnosis, referral, and coding practices, among other potential differences. In 
addition to using automated data, VSD is able to capture data from other data sources, such 
as medical charts and patient interviews. Chart review is important to validate diagnostic 
codes in the automated data, which may be poorly predictive of specific medical conditions 
(e.g., positive predictive value [PPV] of narcolepsy is very low compared to intus-susception 
which has a high PPV), and to obtain additional clinical details and risk factors for specific 
health outcomes.
VSD has evolved and fostered innovation in the databases and methods used to monitor and 
evaluate vaccine safety. At its inception, VSD facilitated the development of the first 
computerized immunization tracking systems at some of the participating sites. In its early 
years, few VSD sites had computerized outpatient clinic data. With the increased utilization 
of computerized data bases in large health care organizations over the years VSD sites built 
electronic capacity, and all sites currently have computerized immunization databases, as 
well as computerized data on outpatient clinic and ED visits and hospitalizations. The sites’ 
electronic health records provide a rich source of information, as they are generated from 
patient care records and include initial diagnoses and test results as well as claims data.
Each site prepares a standardized set of files that contain individual-level data, including 
demographic information, health plan enrollment, birth information, vaccination records, 
hospitalizations, outpatient visits, ED visits, urgent care visits, and other data (Table 2). To 
ensure confidentiality, each site retains its own data. Each member receives a unique, 
randomized VSD identification number that is linked to their health plan member 
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identification number. This link is used only to gather data for the files and is not otherwise 
available. The VSD identification numbers are used to link data across the various databases. 
A standardized data dictionary ensures consistency across sites. Data from medical records 
are frequently used to validate the electronic clinical diagnoses and vaccination data, and 
these are occasionally supplemented with surveys and in-person interviews. All studies must 
meet both local and CDC Institutional Review Board (1RB) and Health Insurance Portability 
and Accountability Act (H1PAA) requirements.
Since its inception, the VSD has led in the development of novel methods for conducting 
prospective vaccine safety surveillance. During its first decade, VSD used a centralized data 
processing model. CDC received de-identified data files to merge into a centralized database 
for analyses. However, in 2001, improvements in technology and heightened awareness of 
confidentiality and security led the VSD to implement the first vaccine safety application of 
the distributed data model. This approach allows each site to control, assemble and maintain 
its data files on its own secure server rather than sending them to CDC [7]. The creation of 
the distributed data model allowed VSD to reinvent the way sites create and use data files. 
Instead of the annually updated “cycle files” with the distributed data model, VSD created 
“dynamic data files” in addition to cycle files. Dynamic data files allow for the continuous 
capturing of information, including vaccinations, hospitalizations, clinic and ED visits, 
health plan enrollment, and certain demographic characteristics. Most dynamic data files are 
updated on a weekly basis. Consequently, this has greatly reduced the time lag until the data 
are available for analysis. CDC can access the dynamic data files through the distributed 
data model on an ongoing basis, thus allowing for near real-time analysis and extraction of 
data for ongoing studies, making it possible to investigate immediate safety concerns.
4. Near real-time monitoring of vaccine safety
Increasingly, policy makers need timely information to develop recommendations and 
provide practical guidance to the public about new potential safety concerns or to provide 
rapid, early safety evaluation of recently licensed vaccines, including annual seasonal 
influenza vaccines. To provide timely data in such situations, VSD researchers developed 
“rapid cycle analysis” (RCA) as a complement to traditional retrospective studies, which 
could take years to complete [9,10]. The RCA process is outlined in Fig. 2. As of 2013, 
VSD had conducted 18 RCAs; this monitoring has included seasonal influenza vaccines 
[11,12], rotavirus vaccine [13,14], human papillomavirus (HPV) vaccine [15], and other 
recently introduced or recommended combination vaccines. The value of RCA for 
identifying vaccine-associated adverse events has been shown for MMRV vaccine among 
children aged 12–23 months [16]. During routine weekly monitoring, a preliminary signal 
was detected for an approximately twofold increased risk of febrile seizures occurring 7–10 
days following MMRV vaccination when compared to separately administered MMR and 
varicella vaccination. These findings, together with nearly identical results from a 
manufacturer-sponsored study based on different methodology, were presented to the CDC’s 
Advisory Committee on Immunization Practices (AC1P), which changed its 
recommendations from a stated preference for MMRV to expressing no preference for 
MMRV or separate MMR plus varicella vaccination [17]. AC1P also recommended that 
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healthcare providers advise parents of this increased risk of fever and seizures when using 
MMRV vaccine in young children.
Another important use of RCA was for monitoring the safety of the 2009 pandemic H1N1 
influenza vaccine. 1n October 2009, once the H1N1 influenza vaccine became available, 
VSD initiated RCA monitoring of the vaccine [18]. This VSD effort occurred 
simultaneously and in close consultation with other DHHS-led efforts and the VSD protocol 
was shared with other organizations that had H1N1 influenza vaccine safety surveillance 
systems, including the Department of Defense, the 1ndian Health Service, FDA’s newly 
developed Post-Licensure Rapid 1mmunization Safety Monitoring (PR1SM) system [19], 
and others [20]. VSD’s important leadership role in safety surveillance and support of 
decision making around H1N1 vaccine was evidenced by its biweekly data reporting to the 
Vaccine Safety Risk Assessment Working Group which was established by the National 
Vaccine Advisory Committee with the charge to conduct independent, rapid reviews of 
available safety monitoring data for the 2009 H1N1 influenza vaccines. The initial VSD 
RCA findings, along with a review of VAERS reports that identified no safety signals, were 
published on December 4, 2009, providing the public early reassuring data on the safety of 
the new vaccine [21].
5. New methodologies to assess vaccine safety
VSD has pioneered development of appropriate statistical methods to evaluate safety signals 
and minimize the chance of having false-positive signals.
With RCA, VSD researchers evaluate the safety of a vaccine on a weekly basis, performing 
multiple analyses over time. The use of traditional statistical methods in this situation, 
however, may generate false positive signals. To address this problem, VSD researchers 
developed the maximized sequential probability ratio test (MaxSPRT). This new signal 
detection method accounts for the repeated statistical testing, supports continuous or time-
period analysis of data as they are collected (e.g., MaxSPRT has been applied weekly within 
VSD) and provides a useful and highly adaptable approach to early detection of adverse 
events after the introduction of new vaccines [22,23]. Using this method, for example, VSD 
investigators identified, earlier than would have been possible with previous methods, a new 
safety signal of febrile seizures associated with 2010–2011 seasonal influenza vaccination 
[12].
VSD investigators have also recently successfully adapted methods used in clinical trials 
known as group sequential analysis to prospectively monitor the safety of new vaccines. 
Using the group sequential monitoring approach, compared to continuous testing (e.g., 
MaxSPRT), less frequent testing is conducted (e.g., at time points based on the number of 
doses administered required to ensure power to detect a pre-specified relative risk) and this 
has the advantage of yielding increased overall study power for a given sample size, which 
may be very important for detecting rare adverse events that were not detected in pre-
licensure studies. This method was used to prospectively monitor the safety of the newly 
introduced DTaP-IPV-Hib and PCV13 vaccines in children during their uptake within VSD 
[24,25]. These studies not only demonstrated the application of this novel method to 
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observational safety data, but also provided reassurance about the safety of these new 
vaccines.
Another novel analytic design developed by VSD investigators is the case-centered approach 
for observational vaccine safety studies. This method uses a “backward” approach, where 
the observed odds of exposure (e.g., immunization) during a certain period of time (i.e., the 
risk interval) prior to the onset of an outcome (e.g., adverse event) are compared with the 
expected odds of exposure during the same risk interval, based on vaccination times in the 
population of similar vaccinees. This is similar to a matched case-control design which uses 
all potential controls. This method has been used in VSD studies of febrile seizures after 
MMRV vaccine [16], Bell’s palsy following influenza vaccine [26], and Guillain–Barré 
Syndrome following vaccinations [27].
MaxSPRT, group sequential analysis, and case-centered analysis have served as a model for 
other types of safety monitoring (e.g., for drugs and medical devices used in the U.S.), and 
for vaccine safety monitoring efforts in other countries.
6. Accomplishments and impact
The resources and capabilities of VSD have enabled investigators both at the sites and at 
CDC to conduct a large variety of studies employing traditional epidemiologic methods that 
require accurate data on vaccinations and other exposures, along with complete capture of 
health outcomes over time. In addition, VSD can be used to study both acute and chronic 
conditions with insidious onset. For example, VSD studies of prenatal and infant exposure to 
thimerosal from vaccines and autism [28], and other neurodevelopmental outcomes [8], 
found no evidence that thimerosal was associated with autism.
VSD also has the ability to study special populations, such as premature infants and 
pregnant women. With recent vaccination policies specifically targeting pregnant women for 
certain vaccines (e.g., influenza, Tdap), VSD has been at the forefront of studying the safety 
of vaccinations administered during pregnancy. The VSD collects information on an 
estimated 125,000 pregnant women annually and has been able to successfully utilize multi-
site electronic healthcare data to identify pregnant women, to ascertain the gestational stage 
of their pregnancy, and to accurately link babies to their mothers. Recently, VSD has 
provided reassuring data on the safety of influenza vaccine in pregnant women [29], and 
studies are ongoing to evaluate TdaP vaccine safety in this population.
In recent years there has been an increase in the number of recommended vaccines included 
in the childhood immunization schedule with resultant interest in addressing the safety of 
multiple vaccinations and the immunization schedule in general [30]. Although policy 
interventions, such as immunization requirements for school entry have resulted in high 
overall immunization coverage in the U.S. one recent VSD study has found evidence of 
marked variability in patterns of adherence (i.e., 1399 distinct vaccination timing patterns 
among 323,247 children at VSD sites) [31]. This variability has allowed VSD to conduct 
initial investigations of the safety of vaccines administered according to different schedules. 
For example, VSD studies have shown an increased risk of seizures following measles 
McNeil et al. Page 7
Vaccine. Author manuscript; available in PMC 2019 September 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
containing vaccines when they are delayed later into the second year of life [32,33], and a 
substantially increased risk of pertussis in children with pertussis containing vaccines 
administered later than the recommended schedule [34].
VSD also has been a highly effective platform for conducting rigorous vaccine safety studies 
in other priority areas, including:
• Safety of newly licensed vaccines (e.g., the safety of herpes zoster vaccine in 
adults [35], and 13-valent pneumococcal conjugate vaccine in children [25]).
• Safety of new recommendations related to existing vaccines (e.g., expanding 
influenza vaccine age indication to include younger age groups [36]).
• Risk of specific clinical disorders associated with immunization (e.g., 
intussusception following rotavirus vaccines [13,14], febrile seizures after TIV 
[12]).
• Vaccine safety in special populations (e.g., risk of spontaneous abortion in 
pregnant women after TIV [29], safety of Tdap vaccine in the elderly [37]).
VSD has conducted important scientific studies (Table 3) to assess the safety of vaccines 
once they are available for use in the United States. Research findings have been published 
in leading peer-reviewed journals; have been presented at regional, national, and 
international scientific conferences; and have informed the deliberations of the 1nstitute of 
Medicine (1OM) and ACIP, that advise on immunization policy [58]. Because of the 
importance of public confidence in the data CDC uses, CDC, National Center for Health 
Statistics (NCHS), and the VSD sites have created novel, secure public-use data sets for 
selected completed VSD studies and established procedures for outside investigators to 
access VSD data under IRB-approved protocols [59,60]. The VSD further ensures 
transparency around its findings through sharing safety data in public sessions, particularly 
at the meetings of ACIP and similar meetings with a broad range of stakeholders.
7. Challenges
VSD has been highly successful in capitalizing on the databases and the scientific resources 
of its sites to conduct innovative and timely assessments of vaccine safety. However, 
electronic healthcare databases are developed for medical care and administrative purposes 
and their use for research can pose challenges. Thus, VSD has developed innovative 
strategies to evaluate the databases to be utilized, linking and compiling them according to a 
standardized data dictionary, and performing rigorous quality checks of the data. Careful 
selection of computerized codes is needed to identify potential cases of each health outcome, 
to avoid misclassification bias that can lead to false positive or false negative findings. 
Moreover, review of individual medical records (either hardcopy or electronic) is often 
critical for validating potential cases identified based on computerized codes.
Health encounter data will only identify those health outcomes that come to medical 
attention. Since the VSD population covers insured members of healthcare organizations, 
lack of access to medical care is not a large concern. However, factors that can influence 
seeking medical care must be kept in mind and addressed in any evaluation conducted in 
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VSD. Likelihood of seeking medical care particularly depends on the severity of a health 
condition. Thus, more severe conditions that lead to hospitalizations are more likely to be 
captured in VSD than less severe conditions for which a person may or may not seek 
medical care. The VSD network, however, can serve as an infrastructure for conducting 
special studies for conditions that are unlikely to be accurately captured in an electronic 
health record. For example, VSD evaluated neurodevelopmental outcomes following infant 
vaccinations with a follow-up study and in-person assessment of cohorts of children who 
had been exposed to different vaccines as infants, conducting neuropsychological tests to 
assess level of functioning on several neurodevelopmental domains [8].
Full ascertainment of vaccination and vaccination coverage can also pose challenges. Since 
vaccinations are a covered benefit of the VSD health plans, there is incentive to receive 
vaccinations within the health plan, and overall vaccine coverage rates are higher than the 
national coverage estimates for the routine infant and childhood vaccines [61]. About 20–
30% of adult influenza vaccinations, however, have been found to be administered in 
nontraditional settings (e.g., pharmacies) outside the health plan and are not captured in the 
VSD immunization tracking systems [62]. VSD analyses are often restricted to vaccinated 
individuals, mainly to address possible biases related to missing vaccinations from outside 
the health plan, as well as “confounding by indication” (e.g., influenza vaccine is more 
likely to be administered to patients with certain underlying high risk medical conditions) 
[63].
Another analytical challenge arises from having a highly vaccinated population, which can 
lead to difficulties in identifying an unvaccinated comparison group. 1n these situations, as 
well as in analyses restricted to vaccinated individuals, various “risk-interval” designs are 
used [64]. Risk interval methods are suitable for acute conditions that tend to occur within a 
limited time period after vaccination. The rate of occurrence of the outcome of interest 
during the risk window is compared with the rate in time periods outside the risk window. 
Self-control methods have built upon the risk interval concept by further restricting analyses 
to vaccinated cases of the outcome of interest [65]. By restricting to vaccinated cases, self-
control methods inherently control for any individual-level potential confounding factor 
(whether measured or not) that does not vary over time. Although risk-interval methods are 
well suited to address acute adverse events, studies of health outcomes with delayed or 
insidious onset can be more challenging.
Since the VSD membership population is comprised largely of employed individuals (and 
their families) with health insurance coverage, questions of generalizability of VSD findings 
often arise. Although the extremes of income distribution may be under-represented, the 
VSD membership populations have been found to have similar demographic characteristics 
to the catchment areas served by the VSD health plans [66].
8. Looking ahead
Since its inception, VSD has been a major contributor to immunization decision making. 
VSD supports the public health mission of CDC and the vaccine safety system through 
optimizing the ability of policy makers to make decisions or to revisit recommendations as 
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new data arise. As a consequence of vaccines’ success in reducing vaccine-preventable 
diseases, focus has shifted to the perceived risks of vaccination in some parents’ minds. 
Vaccine refusal has been increasing in the U.S. and has caused outbreaks in some 
communities [2]. Thus, the role of VSD in monitoring and ensuring vaccine safety has 
become critically important.
The VSD’s dynamic infrastructure has evolved and adapted to changes in medical care 
organization, electronic database diffusion and enhancements, and methodological 
innovations. Looking ahead, we anticipate new opportunities will continue to arise for VSD 
to improve its scope, accuracy and timeliness. Maturing of electronic health records and the 
capability to link records across data systems (such as insurance claims databases and 
immunization registries) may make additional sources of patient data available for post 
licensure epidemiologic evaluations of vaccine safety.
Although diffusion of electronic healthcare records and linkages of large health insurance 
databases may provide substantial increases in the quantity of electronic data available for 
vaccine safety monitoring, VSD’s experience over its first 20 years indicates that data 
quality is perhaps more important than quantity of data for the conduct of scientifically 
sound assessments of vaccine safety. Key to the quality of VSD data has been the ability to 
readily access individual patient records and other detailed clinical information to validate 
computerized diagnostic codes and obtain important information on clinical details and 
patient characteristics. With the universal adoption of electronic health records at all the 
VSD sites, future advances in electronic text mining may provide applications that could 
improve the speed and efficiency of reviewing individual patient records. Most importantly, 
VSD investigators have considerable experience using their health plan data and many of the 
investigators are clinicians that practice in the health plans, providing a practical perspective 
on the strengths and limitations of the data.
9. Conclusions
VSD is a longstanding vaccine safety research network which over the more than 20 years of 
its existence has been a defining force in the area of safety surveillance, not only for 
vaccines but also for other healthcare products, including prescription drugs. Its scientific 
leadership and influence have been widely acknowledged in both the U.S. and around the 
world. VSD has been a model for development of the FDA’s post-marketing surveillance 
Sentinel Network [67], in which all FDA-regulated medical products, including vaccines, 
drugs and medical devices are monitored. Other nations, including a European multi-
national effort [68,69], have adapted systems and methodologies modeled on the VSD (e.g., 
common data dictionaries, the distributed data model and analytic methods such as near real-
time sequential monitoring) in their vaccination safety efforts. VSD has been successful by 
capitalizing on the scientific, organizational and data resources provided by large integrated 
healthcare delivery systems and adapting to changes in medical care structure and advances 
in health information technology. The leadership and experience of VSD investigators and 
the many strengths of VSD provide compelling evidence of its importance as part of the 
overall U.S. vaccination program and as an influential resource providing vaccine 
stakeholders with the best possible information so they can make the best possible decisions. 
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VSD can be expected to continue to evolve along with continuing changes in healthcare 
organization, further computerization of healthcare records and databases, and advances in 
analytical methods.
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Fig. 1. 
Vaccine Safety Datalink Sites 2014. For 2014, Southern California Kaiser Permanente, 
Northern California Kaiser Permanente, Northwest Kaiser Permanente, Group Health 
Cooperative, Kaiser Permanente Colorado, and Marshfield Clinic provide data and subject 
matter expertise; Health Partners, Kaiser Permanente Georgia and Harvard Vanguard 
Medical Associates with Harvard Pilgrim Health Care Institute provide subject matter 
expertise. aHarvard Vanguard Medical Associates with Harvard Pilgrim Health Care 
Institute.
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Fig. 2. 
Rapid CycleAnalysis (RCA) inthe Vaccine Safety Datalink [10].
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Table 1
Number enrolled in the Vaccine Safety Datalink (VSD) compared to the US Census population estimates from 
2010.
 VSD population, 2010 (%)a US population, 2010b,c
<18     2,350,889(3.17)   74,181,467
≥18     7,772,099(3.31) 234,564,071
Births       95,754(2.39)     3,999,386
Total Population
     10,122,938 (3.28)d 308,745,538
a
Percentage of US population.
bUS population estimates obtained from the US Census website (www.census.gov).
cUS birth estimates obtained from the NCHS website (www.cdc.gov/nchs/births.htm).
dCurrent VSD total population in 2012 is 9,491,798 (3.1% of US population).
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 p
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 b
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 m
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 d
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 re
ac
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A
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 a
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lle
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 d
ay
s a
fte
r v
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le
 c
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l c
ris
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N
o 
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 c
hi
ld
re
n
H
am
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dg
e 
et
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l. 
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In
tu
ss
us
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io
n
N
o 
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at
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 p
en
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v
al
en
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ot
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iru
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w
ee
ks
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l. 
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G
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e
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oc
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tio
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flu
en
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 m
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r m
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) b
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1 d
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 c
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 c
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at
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 c
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 c
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 d
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l. 
[3
1]
In
tu
ss
us
ce
pt
io
n
A
ss
oc
ia
tio
n 
w
ith
 m
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w
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 p
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l r
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 p
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 b
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